+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Drug Conjugate Market by Payload Type (Auristatins, Calicheamicins, Maytansinoids), Indication (Breast Cancer, Hematological Cancer, Lung Cancer), Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast 2025-2030- Product Image
Antibody Drug Conjugate Market by Payload Type (Auristatins, Calicheamicins, Maytansinoids), Indication (Breast Cancer, Hematological Cancer, Lung Cancer), Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast 2025-2030- Product Image
Sale

Antibody Drug Conjugate Market by Payload Type (Auristatins, Calicheamicins, Maytansinoids), Indication (Breast Cancer, Hematological Cancer, Lung Cancer), Stage Of Development, Linker Type, Antibody Type, Conjugation Technology - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5896370
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antibody drug conjugate market is rapidly evolving, redefining standards in targeted oncology care and biopharmaceutical innovation. Senior decision-makers require actionable insights to navigate shifting dynamics and leverage emerging opportunities as technologies and regulatory frameworks mature.

Market Snapshot: Antibody Drug Conjugate Market Growth and Opportunities

The Antibody Drug Conjugate (ADC) Market expanded from USD 6.48 billion in 2024 to USD 7.55 billion in 2025 and is projected to grow at a CAGR of 16.24%, reaching USD 15.99 billion by 2030. This robust trajectory is fueled by the adoption of next-generation targeted therapeutics in oncology and the increasing pipeline activity from both established pharmaceutical leaders and innovative biotech firms. Biopharma enterprises and investors are intensifying their focus on ADCs as these modalities demonstrate the potential to address treatment-resistant cancers and reduce off-target toxicity, significantly improving patient outcomes and market demand.

Scope & Segmentation of the Antibody Drug Conjugate Market

This comprehensive report provides a detailed breakdown across vital segmentation areas, enabling targeted strategy formulation:

  • Payload Types: Auristatins (MMAE, MMAF), Calicheamicins (N-Acetyl-Gamma-Calicheamicin), Maytansinoids (DM1, DM4)
  • Indications: Breast Cancer (HER2 Positive, Triple Negative), Hematological Cancers (Leukemia, Lymphoma, Myeloma), Lung Cancer
  • Stage of Development: Approved, Phase I, Phase II, Phase III, Preclinical candidates
  • Linker Types: Cleavable (Acid, Disulfide, Protease Cleavable), Non Cleavable (Thioether)
  • Antibody Types: Chimeric, Human, Humanized, Murine
  • Conjugation Technologies: Conventional Conjugation, Site Specific Conjugation (Enzyme Based, Glycoengineering)
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with coverage spanning the UK, Germany, France, UAE, South Africa, among others), Asia-Pacific (China, India, Japan, Australia, South Korea, and more)
  • Leading Companies: Roche Holding AG, Seagen Inc., Daiichi Sankyo Company, Limited, Pfizer Inc., AstraZeneca plc, ImmunoGen, Inc., AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Astellas Pharma Inc.

Key Takeaways for Antibody Drug Conjugate Stakeholders

  • Antibody drug conjugates leverage monoclonal antibody specificity integrated with potent cytotoxic agents, facilitating more precise targeting of malignant cells while reducing systemic side effects.
  • Recent advances in linker design and site-specific conjugation have enhanced payload stability, pharmacokinetics, and batch consistency—crucial for scaling commercial production and optimizing therapeutic indices.
  • Clinical innovation is expanding ADC use cases beyond oncology, including potential autoimmune therapy applications, as interdisciplinary R&D teams drive platform versatility.
  • Regional regulatory and partnership variances influence development speed and market entry strategies. Certain markets benefit from harmonized frameworks and investment incentives accelerating product launches.
  • Strategic collaborations, such as alliances between biotechs, pharma, academic institutions, and contract manufacturers, are reshaping the innovation landscape, sharing risk and pooling expertise for faster translation to clinical and commercial stages.
  • Investment in workforce training and local infrastructure is rising, particularly as companies adapt to changes in import duty and strive for supply chain resilience.

Tariff Impact: Navigating Shifts in US Import Tariffs

Recent changes in United States import tariffs on key ADC manufacturing intermediates have directly affected global supply chain strategies. Companies are moving to diversify suppliers, incorporate more domestic and nearshore partners, and build partnerships with contract development and manufacturing organizations equipped with vertically integrated operations. Onshoring of critical steps, such as antibody expression and linker-payload conjugation, is being prioritized. These shifts increase supply chain resilience, manage cost pressures, and reduce exposure to regulatory fluctuations while maintaining product quality and delivery timelines.

Methodology & Data Sources

This research is grounded in a multidimensional methodology, incorporating thorough secondary research of scientific publications, patent databases, and clinical trial registries. Cross-validation with proprietary datasets ensures analytical confidence. Structured interviews with domain experts across academia and industry confirm emerging trends and inform nuanced segment perspectives, complemented by comparative analysis of regulatory, clinical, and supply chain benchmarks.

Why This Report Matters to Senior Leaders

  • Enables data-driven decision-making for investment, partnership, and development strategies across all ADC segments and geographies.
  • Offers clarity on regulatory, supply chain, and technology trends with direct implications for operational agility, risk management, and competitive positioning.
  • Provides actionable guidance for anticipating market shifts, segment priorities, and optimal technology adoption within a rapidly changing landscape.

Conclusion

The antibody drug conjugate market is poised for continued transformation as next-generation technologies emerge and global adoption accelerates. Stakeholders who use actionable market intelligence will be well-positioned to drive meaningful impact in oncology and beyond, navigating complexity with confidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of site-specific conjugation techniques to improve ADC safety and efficacy
5.2. Integration of novel cytotoxic payloads in next-generation ADCs targeting resistant tumor clones
5.3. Advancement in cleavable linker technologies allowing controlled drug release in tumor microenvironments
5.4. Application of artificial intelligence for optimizing ADC candidate selection and structure-activity modeling
5.5. Expansion of antibody drug conjugate pipelines to solid tumors by overcoming delivery barriers and heterogeneity
5.6. Evolution of regulatory frameworks supporting expedited approval pathways for innovative ADC therapies
5.7. Implementation of continuous manufacturing platforms to enhance scalability and reduce ADC production costs
5.8. Strategic collaborations between biotech startups and Big Pharma to co-develop proprietary ADC platforms
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antibody Drug Conjugate Market, by Payload Type
8.1. Introduction
8.2. Auristatins
8.2.1. Mmae
8.2.2. Mmaf
8.3. Calicheamicins
8.3.1. N Acetyl Gamma Calicheamicin
8.4. Maytansinoids
8.4.1. Dm1
8.4.2. Dm4
9. Antibody Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.2.1. Her2 Positive
9.2.2. Triple Negative
9.3. Hematological Cancer
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Myeloma
9.4. Lung Cancer
10. Antibody Drug Conjugate Market, by Stage Of Development
10.1. Introduction
10.2. Approved
10.3. Phase I
10.4. Phase Ii
10.5. Phase Iii
10.6. Preclinical
11. Antibody Drug Conjugate Market, by Linker Type
11.1. Introduction
11.2. Cleavable
11.2.1. Acid Cleavable
11.2.2. Disulfide Cleavable
11.2.3. Protease Cleavable
11.3. Non Cleavable
11.3.1. Thioether
12. Antibody Drug Conjugate Market, by Antibody Type
12.1. Introduction
12.2. Chimeric
12.3. Human
12.4. Humanized
12.5. Murine
13. Antibody Drug Conjugate Market, by Conjugation Technology
13.1. Introduction
13.2. Conventional Conjugation
13.3. Site Specific Conjugation
13.3.1. Enzyme Based
13.3.2. Glycoengineering
14. Americas Antibody Drug Conjugate Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antibody Drug Conjugate Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antibody Drug Conjugate Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Roche Holding AG
17.3.2. Seagen Inc.
17.3.3. Daiichi Sankyo Company, Limited
17.3.4. Pfizer Inc.
17.3.5. AstraZeneca plc
17.3.6. ImmunoGen, Inc.
17.3.7. AbbVie Inc.
17.3.8. Amgen Inc.
17.3.9. GlaxoSmithKline plc
17.3.10. Astellas Pharma Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTIBODY DRUG CONJUGATE MARKET: RESEARCHAI
FIGURE 28. ANTIBODY DRUG CONJUGATE MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTIBODY DRUG CONJUGATE MARKET: RESEARCHCONTACTS
FIGURE 30. ANTIBODY DRUG CONJUGATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAF, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MMAF, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY N ACETYL GAMMA CALICHEAMICIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY N ACETYL GAMMA CALICHEAMICIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM1, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM1, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM4, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DM4, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PROTEASE CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PROTEASE CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY THIOETHER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY THIOETHER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONVENTIONAL CONJUGATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONVENTIONAL CONJUGATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYME BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYME BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY GLYCOENGINEERING, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY GLYCOENGINEERING, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 167. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 168. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 169. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 170. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 171. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 172. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 173. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 174. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 175. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 178. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 179. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 180. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 181. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 182. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 183. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 184. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 185. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 186. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 187. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 188. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 189. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 190. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 191. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 192. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 193. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 194. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 213. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 215. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 216. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 217. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 218. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 219. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 220. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 221. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 222. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HEMATOLOGICAL CANCER, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CONJUGATION TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SITE SPECIFIC CONJUGATION, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AURISTATINS, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CALICHEAMICINS, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MAYTANSINOIDS, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antibody Drug Conjugate market report include:
  • Roche Holding AG
  • Seagen Inc.
  • Daiichi Sankyo Company, Limited
  • Pfizer Inc.
  • AstraZeneca plc
  • ImmunoGen, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • GlaxoSmithKline plc
  • Astellas Pharma Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.55 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.99 Billion
Compound Annual Growth Rate16.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antibody Drug Conjugates Contract Manufacturing Market by Type (Clinical, Commercial), Service Offered (End-to-End Manufacturing, Standalone / Modular Services), Payload Type, Linker Type, Application - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Type (Clinical, Commercial), Service Offered (End-to-End Manufacturing, Standalone / Modular Services), Payload Type, Linker Type, Application - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - Product Image

Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions

  • Report
  • 716 Pages
  • Global
From
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography - Product Image

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

  • Report
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing - Global Strategic Business Report - Product Image

Antibody Drug Conjugates Contract Manufacturing - Global Strategic Business Report

  • Report
  • 168 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.